Evidence map›Paper›PMID 36556457›Full record

ArticleLife (Basel, Switzerland)2022

Baseline Ang-2 Serum Levels as a Predictive Factor for Survival in NSCLC and SCLC.

Asimina Nikolakopoulou, Dimitris Tsakogiannis, Flora Zagouri, Eleni Zografos, Lamprini Tzioga, Grigorios Stratakos, Nikolaos Koulouris, Konstantinos Syrigos, Garyfalia Bletsa

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Asimina Nikolakopoulou1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Dimitris TsakogiannisResearch Center, Hellenic Anticancer Institute, 10680 Athens, Greece.ORCID 0000-0001-6835-8410
Flora ZagouriDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, 11528 Athens, Greece.
Eleni ZografosDepartment of Clinical Therapeutics, Alexandra Hospital, National and Kapodistrian University of Athens School of Medicine, 11528 Athens, Greece.ORCID 0000-0002-9540-7553
Lamprini TziogaResearch Center, Hellenic Anticancer Institute, 10680 Athens, Greece.
Grigorios Stratakos1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-5861-3454
Nikolaos Koulouris1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-1719-7220
Konstantinos SyrigosThird Department of Internal Medicine, Sotiria Hospital, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Garyfalia BletsaResearch Center, Hellenic Anticancer Institute, 10680 Athens, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Angiopoietin-2 (Ang-2) has been implicated in the development of several types of cancer, including lung malignancy. In the present study, we examined the impact of Ang-2 serum concentration on the development, dissemination, and 5-year overall survival of NSCLC and SCLC. A total of 99 patients with lung cancer were tested. The OS of NSCLC and SCLC patients was estimated using Kaplan−Meier curves and compared through log-rank test. The median serum level of Ang-2 at baseline in both NSCLC and SCLC patients was significantly higher than that of controls (p < 0.0001). The Ang-2 serum concentration was not related to metastasis, neither in NSCLC nor in SCLC cases. The OS was found to be significantly shorter for stage IIIβ NSCLC patients with a high baseline Ang-2 serum concentration (p = 0.012), while Cox regression analysis showed that Ang-2 is a significant independent factor for poor prognosis for stage IIIβ NSCLC (hazard ratio = 2.97, 95% CI: 1.05−8.40, p = 0.04). The concentration of Ang-2 has no impact on the prognosis of SCLC. Ang-2 could be considered as a significant molecular marker that enables the prediction of NSCLC and SCLC development, and is involved in the poor prognosis of stage IIIβ NSCLC.

Indexed as

Ang-2angiopoietinslung cancerNSCLCprognostic factorSCLC

Identifiers

PMID36556457
PMCPMC9786126
OpenAlexW4311367492

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.